Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Merck Kgaa Dm 5 (MKGAF)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTHER OTC]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTHER OTC]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 12,655,828
  • Shares Outstanding, K 129,240
  • Annual Sales, $ 17,324 M
  • Annual Income, $ 2,939 M
  • 36-Month Beta 0.75
  • Price/Sales 0.73
  • Price/Cash Flow 2.52
  • Price/Book 0.80
  • Price/Earnings ttm 14.02
  • Earnings Per Share ttm 6.93
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 06/21/18
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
94.4000 +3.73%
on 05/16/18
103.6693 -5.54%
on 05/30/18
-2.7750 (-2.76%)
since 05/14/18
3-Month
92.3800 +6.00%
on 03/26/18
103.6693 -5.54%
on 05/30/18
+3.0750 (+3.24%)
since 03/08/18
52-Week
92.3800 +6.00%
on 03/26/18
123.6580 -20.81%
on 06/27/17
-22.7350 (-18.84%)
since 06/13/17

Most Recent Stories

More News
Merck KGaA (MKGAF) Q1 Earnings and Revenues Decline Y/Y

Merck KGaA (MKGAF) reports dismal first-quarter results with earnings declining year over year. Revenues fall due to continued negative currency movement.

PG : 77.43 (+1.30%)
BMRN : 99.03 (+0.61%)
PFE : 36.51 (+0.58%)
MKGAF : 97.9250 (+0.80%)
What's in the Cards for Merck KGaA (MKGAF) in Q1 Earnings?

Merck's (MKGAF) Healthcare and Life Science segments to drive sales in Q1. However, operating expense is expected to be higher to support the launch of Bavencio and Mavenclad.

ARQL : 4.76 (+1.49%)
SMMT : 12.35 (-7.49%)
PFE : 36.51 (+0.58%)
MKGAF : 97.9250 (+0.80%)
Pfizer's Kidney Cancer Drug Misses Endpoint in Phase III

Pfizer's (PFE) kidney cancer drug Inlyta (axitinib) fails to demonstrate a clear improvement in the primary endpoint of extending disease-free survival (DFS) in a late-stage study.

MRK : 61.47 (+0.47%)
PFE : 36.51 (+0.58%)
GSK : 40.89 (+0.20%)
MKGAF : 97.9250 (+0.80%)
Merck KGaA's Tepotinib Gets Fast Track Designation in Japan

Merck KGaA's (MKGAF) lung cancer candidate, tepotinib gets fast track designation in Japan.

MRK : 61.47 (+0.47%)
PFE : 36.51 (+0.58%)
MKGAF : 97.9250 (+0.80%)
BMY : 55.14 (+2.22%)
Merck KGaA (MKGAF) Q4 Earnings Flat Y/Y, Sales Up

Merck KGaA (MKGAF) reports a mixed fourth-quarter with earnings remaining flat year-over-year while sales is up.

MKGAF : 97.9250 (+0.80%)
What's in the Cards for Merck KGaA (MKGAF) in Q4 Earnings?

Merck's (MKGAF) Healthcare and Life Science segments are likely to drive sales in Q4. However, the company's oncology drug fails in a phase III gastric cancer study.

GEMP : 5.75 (-8.59%)
CLDX : 0.52 (-6.64%)
PFE : 36.51 (+0.58%)
MKGAF : 97.9250 (+0.80%)
Vertex (VRTX) Q4 Earnings Beat on Strong CF Products Sales

Vertex Pharma (VRTX) fourth-quarter earnings increase from the year-ago period led by strong sales of CF drugs and lower operating expenses.

CNCE : 19.37 (-1.37%)
JNJ : 122.84 (+1.14%)
VRTX : 159.19 (+1.67%)
MKGAF : 97.9250 (+0.80%)
Roche MS Drug Ocrevus Gets Marketing Authorization in Europe

Roche's (RHHBY) multiple sclerosis drug Ocrevus gets approval in Europe thereby boosting its neuroscience portfolio. The drug is already approved in the United States.

EXEL : 20.04 (-1.57%)
RHHBY : 27.7700 (+2.51%)
MKGAF : 97.9250 (+0.80%)
BIIB : 296.04 (-0.44%)
What's Happening in Advanced Renal Cell Carcinoma Space?

The advanced renal cell carcinoma space is back in focus as the FDA approved Cabometyx for treatment-naive patients. Investors will keep an eye on other combination therapies being evaluated for the treatment...

MRK : 61.47 (+0.47%)
NVS : 75.06 (+1.46%)
EXEL : 20.04 (-1.57%)
RHHBY : 27.7700 (+2.51%)
PFE : 36.51 (+0.58%)
MKGAF : 97.9250 (+0.80%)
BMY : 55.14 (+2.22%)
Merck KGaA (MKGAF) Q3 Earnings Decline Y/Y, Revenues Flat

Merck KGaA (MKGAF) reported dismal third-quarter results with earnings declining year over year. Revenues were flat amid continued negative currency movement.

RHHBY : 27.7700 (+2.51%)
PFE : 36.51 (+0.58%)
MKGAF : 97.9250 (+0.80%)
BMY : 55.14 (+2.22%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade MKGAF with:

Key Turning Points

2nd Resistance Point 97.9250
1st Resistance Point 97.9250
Last Price 97.9250
1st Support Level 97.9250
2nd Support Level 97.9250

See More

52-Week High 123.6580
Fibonacci 61.8% 111.7098
Fibonacci 50% 108.0190
Fibonacci 38.2% 104.3282
Last Price 97.9250
52-Week Low 92.3800

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar